A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos(R))] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

Conclusions: CPX-351 100 Units/m2/dose on Days 1, 3, and 5 was well tolerated in this pediatric population and has promising activity in children and young adults with R/R AML. Additional CNS directed therapy is recommended for pediatric patients at high risk for failure in the CNS.DisclosuresPhillips: Novartis AG: Consultancy. An: Jazz Pharmaceuticals: Employment.

Source: Blood - November 21, 2018 Category: Hematology Authors: Absalon, M. J., Breese, E. H., Lee, L., O'Brien, M. M., Phillips, C. L., Burns, K., Mizukawa, B., An, Q., Mangino, J., Kaplan, J., Norris, R., Perentesis, J. P. Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Combination Therapy Source Type: research